Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.
You may also be interested in...
Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning
Following panel recommendation, label includes warning of use of bezlotoxumab in patients with history of congestive heart failure; postmarketing commitments include studies on microbial retention and endotoxin recovery.
Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
Evolution of Rx Drug Promotion: Researchers Eye Data Brokers, Digital Tools, Global Influencers
US FDA staff acknowledge the challenge of assessing promotions on the internet as experts note trends and topics for future research, including the use of metadata and embedded advertisements, TikTok promotions, and DTC ads extending into countries that prohibit them.